Functional echocardiography for management of shock in neonates- a randomized clinical trial
In brief
Echo-guided care leaves 74% of neonates with shock off inotropes at 72 hours
In a single-center randomized trial, 74% of neonates managed with functional echocardiography plus clinical assessment were alive without inotropic support at 72 hours, compared with 33% receiving clinical assessment alone. They reached hemodynamic stability sooner, but survival to discharge and severe brain injury did not differ significantly; larger multicenter trials are needed to clarify those outcomes.
- Journal
- European journal of pediatrics (Q1)
- Published
- 18 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Yaseer A Mir, Deepak Chawla, Suksham Jain, Lipi Uppal, Supreet Khurana, Harshit Kumar, et al.
- PMID
- 43052408
- DOI
- 10.1007/s00431-026-07634-7
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (paper of the day, 21 November 2026): Randomized trial of echocardiography-guided neonatal shock management
Abstract
UNLABELLED: Neonatal shock is associated with a high case fatality rate. Detection and management of shock by monitoring only clinical parameters may be inadequate due to inconsistent association with tissue perfusion. We evaluated the efficacy of adding functional echocardiography to standard clinical assessment in improving short-term outcome in neonates with shock. This was an open-labelled randomized clinical trial conducted in level III NICU of a tertiary care hospital in India. Neonates born at 28-42 completed weeks of gestation and developing shock defined by presence of at least two of seven prespecified criteria: tachycardia, hypotension, prolonged capillary refilling time, low perfusion index, increased central-to-peripheral temperature difference, oliguria and metabolic acidosis were randomized into two groups: Echo group-shock managed using both standard clinical assessment and functional echocardiography and, Clinical group- shock managed using only standard clinical assessment. Primary outcome was survival without inotropic support at 72 h post-randomization. Secondary outcomes were time to hemodynamic stability, survival to discharge and severe intraventricular hemorrhage or cystic periventricular leukomalacia. Baseline characteristics were largely comparable in the two groups. Survival without inotropic support at 72 h was observed in 28 (73.7%) of 38 neonates in the Echo group and 13 (33.3%) of 39 neonates in the Clinical group (RR, 2.21; 95% CI, 1.36-3.58, P = 0.0004; adjusted RR, 2.18; 95% CI, 1.33-3.59). Hemodynamic stability was reached earlier in the Echo group (median, 3 vs. 5 h; P = .001). Survival to discharge (73.7% vs. 59.0%; RR, 1.25; 95% CI, 0.90-1.73) and severe intraventricular hemorrhage or cystic periventricular leukomalacia (10.5% vs. 7.7%) did not differ significantly. CONCLUSIONS: In this single-center, open-label trial, adding protocolized functional echocardiography to clinical assessment increased survival without inotropic support at 72 h after randomization. Survival to discharge and severe brain injury did not differ significantly; the trial was not powered for these outcomes. Multicenter trials with blinded outcome assessment are needed. TRIAL REGISTRATION: Clinical Trial Registry of India Identifier (CTRI/2023/08/056672), registered on 21st august 2023. WHAT IS KNOWN: • Diagnosis of neonatal shock and initiating inotropes solely on the basis of clinical parameters like low BP or isolated tachycardia does not address the underlying physiology. • This practice may not help match the pharmacological action of drug to underlying cause. WHAT IS NEW: • In a randomized trial of neonates with shock, adding protocolized functional echocardiography to clinical assessment increased survival without inotropic support at 72 h (74% vs. 33%). • Effects on survival to discharge (74% vs. 59%) and severe brain injury were imprecise; multicenter trials are needed before routine use.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.